Psykose ved parkinsons sykdom

Tidsskrift for den Norske Laegeforening

Volumn 132, Issue 2, 2012, Pages 155-158

  Rongve, Arvid ^a   Auning, Eirik ^b   Ehrt, Uwe ^a   Årsland, Dag ^a  

^a Stavanger universitetssjukehus ^*  (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; PARKINSON DISEASE; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW;

ANTIPSYCHOTIC AGENTS; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 84858316995     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.11.0723     Document Type: Article

References (53)

1. Aarsland D, Pedersen KF, Ehrt U et al. Nevropsykiatriske og kognitive symptomer ved Parkinsons sykdom. Tidsskr Nor Legeforen 2008; 128: 2072 - 6.
2. Rabey JM, Prokhorov T, Miniovitz A et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007; 22: 313 - 8.
3. Merims D, Balas M, Peretz C et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29: 331 - 7.
4. Kurlan R, Cummings J, Raman R et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356 - 63.
5. Ondo WG, Tintner R, Voung KD et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958 - 63.
6. Shotbolt P, Samuel M, Fox C et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009; 5: 327 - 32.
7. Fernandez HH, Okun MS, Rodriguez RL et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinicalpolysomnography study. Int J Neurosci 2009; 119: 2196 - 205.
8. Meltzer HY, Mills R, Revell S et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010; 35: 881 - 92.
9. Low-dose clozapine for the treatment of druginduced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757 - 63.
10. Pollak P, Tison F, Rascol O et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689 - 95.
11. Morgante L, Epifanio A, Spina E et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002; 23 (suppl 2): S89 - 90.
12. Breier A, Sutton VK, Feldman PD et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52: 438 - 45.
13. Ondo WG, Levy JK, Vuong KD et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17: 1031 - 5.
14. Goetz CG, Blasucci LM, Leurgans S et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789 - 94.
15. Aarsland D, Brønnick K, Alves G et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 928 - 30.
16. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289: 12 - 7.
17. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734 - 8.
18. Aarsland D, Larsen JP, Cummins JL et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595 - 601.
19. Aarsland D, Brønnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36 - 42.
20. Forsaa EB, Larsen JP, Wentzel-Larsen T et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996 - 1001.
21. Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61: 1906 - 11.
22. Aarsland D, Larsen JP, Karlsen K et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866 - 74.
23. Uc EY, Struck LK, Rodnitzky RL et al. Predictors of weight loss in Parkinson's disease. Mov Disord 2006; 21: 930 - 6.
24. Aarsland D, Larsen JP, Tandberg E et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938 - 42.
25. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669 - 71.
26. Ravina B, Marder K, Fernandez HH et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061 - 8.
27. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (suppl 6): S10 - 6.
28. Baker WL, Silver D, White CM et al. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord 2009; 15: 287 - 94.
29. Halliday G, Hely M, Reid W et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409 - 15.
30. Kataoka H, Furiya Y, Morikawa M et al. Increased temporal blood flow associated with visual hallucinations in Parkinson's disease with dementia. Movement disorders: official journal of the Movement Disorder Society 2008; 23: 464 - 5.
31. Boecker H, Ceballos-Baumann AO, Volk D et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007; 64: 984 - 8.
32. Rascol O, Payoux P, Ory F et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53 Suppl 3: S3 - 12; discussion S-5.
33. Meppelink AM, de Jong BM, Renken R et al. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009; 132: 2980 - 93.
34. Nomura T, Inoue Y, Mitani H et al. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 2003; 18: 812 - 7.
35. Manni R, Pacchetti C, Terzaghi M et al. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology 2002; 59: 1979 - 81.
36. Meppelink AM, Koerts J, Borg M et al. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Movement disorders: official journal of the Movement Disorder Society 2008; 23: 1906 - 12.
37. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995; 28: 240 - 58.
38. Nasjonalt kompetansesenter for bevegelsesforstyrrelser. Veiledende retningslinjer for diagnostisering og behandling ved Parkinsons sykdom. Stavanger: Stavanger universitetssjukehus, 2010. http://www.sus.no/omoss/avdelinger/nasjonaltkompetansesenter-for-bevegelsesforstyrrelser/Documents/Retningslinjer%202010%20 Parkinsons%20sykdom%20web.pdf%2012%2004%2010.pdf (9.12.2011)
39. Miyasaki JM, Shannon K, Voon V et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996 - 1002.
40. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord 2003; 18: 831 - 2.
41. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001; 14: 499 - 504.
42. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Movement disorders: official journal of the Movement Disorder Society 2008; 23: 1541 - 5.
43. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99 (suppl 1): 18 - 27.
44. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225 - 9.
45. Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 2010; 33: 14 - 6.
46. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509 - 18.
47. Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899 - 907.
48. Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151 - 7.
49. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebocontrolled trials. JAMA 2005; 294: 1934 - 43.
50. Herrmann N, Li A, Lanctôt K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother 2011; 12: 787 - 800.
51. Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613 - 8.
52. Litvinenko IV, Odinak MM, Mogil'naya VI et al. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neurosci Behav Physiol 2010; 40: 149 - 55.
53. Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, doubleblind, placebo-controlled trial. Lancet Neurol 2010; 9: 969 - 77.